3-MATIDA

Discontinued Product

3-MATIDA (Cat. No. 2196) has been withdrawn from sale for commercial reasons.
Description: Potent and selective mGlu1 antagonist
Chemical Name: α-Amino-5-carboxy-3-methyl-2-thiopheneacetic acid
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (5)

Biological Activity for 3-MATIDA

Potent metabotropic glutamate mGlu1 receptor antagonist (IC50 = 6.3 μM at rat mGlu1a). Displays ≥ 40-fold selectivity over other receptors: mGlu5, mGlu2, mGlu4a (IC50 > 300 μM), NMDA and AMPA (IC50 = 250 μM). Neuroprotective in cultured murine cortical cells and rat hippocampal slice cultures in vitro. Reduces the volume of ischemia-induced brain infarcts in rats following systemic administration in vivo.

Technical Data for 3-MATIDA

M. Wt 215.23
Formula C8H9NO4S
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 518357-51-2
PubChem ID 10398360
InChI Key KOMWRBFEDDEWEP-UHFFFAOYSA-N
Smiles CC1=C(SC(=C1)C(O)=O)C(N)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Antagonists

Keywords: 3-MATIDA, 3-MATIDA supplier, Potent, selective, mGlu1, mGluR1, antagonists, mGlur, Group, I, Receptors, mGlu5, mGluR5, Glutamate, Metabotropic, (Metabotropic), 2196, Tocris Bioscience

1 Citation for 3-MATIDA

Citations are publications that use Tocris products. Selected citations for 3-MATIDA include:

Zheng and Raman (2011) Prolonged postinhibitory rebound firing in the cerebellar nuclei mediated by group I metabotropic glutamate receptor potentiation of L-type calcium currents. J Neurosci 31 10283 PMID: 21753005


Reviews for 3-MATIDA

There are currently no reviews for this product. Be the first to review 3-MATIDA and earn rewards!

Have you used 3-MATIDA?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.